Document is current
Any future updates will be listed below
-
Authors
Pelagatti, Lorenzo https://orcid.org/0000-0003-1849-8372
Mangani, Francesca
Muz, Elisa
Corbetta, Lorenzo https://orcid.org/0000-0001-6733-4935
Tomassetti, Sara https://orcid.org/0000-0002-4781-6539
Farese, Alberto https://orcid.org/0009-0002-7877-0462
Bartoloni, Alessandro https://orcid.org/0000-0001-9758-1523
Caldi, Francesca
Ronchetti, Mattia https://orcid.org/0009-0003-7037-9546
Giani, Tommaso https://orcid.org/0000-0001-7293-058X
Nazerian, Peiman https://orcid.org/0000-0003-1072-9148
Rossolini, Gian Maria https://orcid.org/0000-0002-9386-0434
Vanni, Simone https://orcid.org/0000-0002-1201-5715
-
Funding
Funding for this research was provided by:
Università degli Studi di Firenze
- License Information
-
More Information
Article History
Received: 9 October 2025
Accepted: 2 December 2025
First Online: 10 December 2025
Declarations
:
: The study protocol (CEAVC 26198_oss) was approved by the Tuscany Regional Ethics Committee (ClinicalTrials.gov: NCT06506617).
: Written informed consent was obtained from participants to participate in the study.
: The authors have no conflicts of interest to declare in relation to this study.Outside this study, GMR reports grants or contracts to the laboratory from Ada, Alifax, Arrow Diagnostics, Biomedical Service, bioMérieux, Cepheid, Menarini, MSD, Qlinea, Qvella, SD Biosensor, Seegene, Shionogi; consulting fees from Advanz Pharma, bioMérieux, Deepull, MSD, Viatris; honoraria for lectures, presentations, manuscript writing or educational events by bioMérieux, Menarini, MSD, Pfizer, Shionogi, Relab.
